For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Adverse events over time

Prolonged therapy with Tafinlar + Mekinist demonstrated a trend toward a decrease in the incidence of AEs over time1

Adverse event incidences for Tafinlar® (dabrafenib) + Mekinist® (trametinib) patients

  • Combined data from patients who received Tafinlar + Mekinist for ≥ 24 months across the 3 randomized studies demonstrated1:
    • The highest incidence of AEs occurred early in therapy (between 0-6 months)
    • Over time, the incidence of the majority of AEs decreased with prolonged exposure


AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Reference: 1. Novartis. Data on file.